Tag: Cancer: Lung
Perioperative Nivolumab Beneficial for Resectable NSCLC
Perioperative nivolumab showed event-free survival benefit from time of surgery compared with neoadjuvant nivolumab
Alternative Explanation Conditions Often Delay Lung Cancer Diagnosis
Having two or more alternative explanation conditions delays lung cancer diagnosis by 74 days
Radiotherapy Dose to Cardiac Substructures Linked to Arrhythmias
After adjustment for baseline cardiovascular risk, pulmonary vein volume receiving 5 Gy linked to atrial fibrillation
Alternative Criteria Can ID High-Benefit Groups for Lung Cancer Screening
Alternative criteria included people who smoked any amount for at least 40 years; people aged 60 to 80 years with 40 pack-years of smoking
Rheumatoid Arthritis Tied to Higher Risk for Lung Cancer
Rheumatoid arthritis-interstitial lung disease shows particularly high risk
Most Americans Don’t Know About Lung Cancer Screening: Survey
Intensity-Modulated Radiotherapy Recommended for Locally Advanced Lung Cancer
Patients receiving IMRT and three-dimensional conformal radiotherapy appear to have similar rates of developing secondary cancer
E-Cigarette Use Linked to Lower Use of Lung Cancer Screening
Similar findings seen for those who previously used combustible cigarettes and currently use electronic cigarettes
Amivantamab-Lazertinib Ups Survival in EGFR-Mutated Advanced Lung Cancer
Improved progression-free survival seen for amivantamab-lazertinib versus osimertinib as first-line treatment
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is Low
Increase in UTD-LCS prevalence seen with age and number of comorbidities; relatively lower levels seen in Southern states
